Quarterly ResultAug 13, 2026, 04:35 PM
Eledon Pharma Reports $70.7M Net Loss YTD; Going Concern Doubt
AI Summary
Eledon Pharmaceuticals reported a net loss of $70.7 million for the six months ended June 30, 2026, and $31.6 million for the quarter. The company's cash, cash equivalents, and short-term investments totaled $88.8 million. Management has concluded that substantial doubt exists about the company's ability to continue as a going concern due to insufficient funding for planned operations.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $(70.655) million.
- Net loss for the three months ended June 30, 2026, was $(31.630) million.
- Cash and cash equivalents as of June 30, 2026, totaled $6.803 million.
- Short-term investments as of June 30, 2026, were $81.953 million.
- Total current assets as of June 30, 2026, were $93.091 million.
- Accumulated deficit as of June 30, 2026, reached $(471.858) million.
- Research and development expenses for the six months ended June 30, 2026, were $35.427 million.
- Change in fair value of warrant liabilities for the six months ended June 30, 2026, was $(28.585) million.
Price Impact
More from ELDN